RARE Daily - Global Genes

Articles

Rare Advocate

May 13, 2021

Rare Leader: Julie Breneiser, Executive Director, Gorlin Syndrome Alliance

Finance

May 13, 2021

SpliSense Secures $28.5 Million in Series B Financing Including Backing from CFF

Finance

May 13, 2021

Flare Launches with $82 Million to Advance Novel Drug Discovery Approach for Transcription Factors

Finance

May 13, 2021

Magenta Raises $86.4 Million to Advance Novel Antibody-Drug Conjugate Conditioning Platform

Policy

May 13, 2021

Rare Disease Drug Developers Form Coalition to Address Challenges

Deals

May 13, 2021

CRO Emmes Acquires UK-Based Orphan Reach

Deals

May 12, 2021

MD Anderson and Broad Institute Launch Translational Research Platform Focused on Rare Cancers

Finance

May 12, 2021

Huma Raises $200 Million to Scale Digital Health Platform for Better Care and Research

Finance

May 12, 2021

Gennao Bio Closes $40 Million in Financing to Develop Pipeline of Targeted Nucleic Acid Therapeutics

Drug Development

May 12, 2021

FDA Grants Fulcrum Fast Track for FSHD Drug

Finance

May 12, 2021

Xontogeny Seeds NephroDI to Develop a Treatment for Nephrogenic Diabetes Insipidus

Research

May 11, 2021

Gene Therapy Restores Immune Function in Children with Rare Immunodeficiency

Deals

May 11, 2021

Biogen Enters Collaboration with Capsigen for AAV Capsids for CNS and Neuromuscular Disorders

Research

May 11, 2021

Mutations Cause Rare Genetic Disease in Children

Uncategorized

May 11, 2021

FDA Halts Rocket Pharma Trial of Experimental Gene Therapy for Danon Disease

Drug Development

May 10, 2021

Laronde Unveiled to Advance New Class of Programmable Medicines

Drug Development

May 10, 2021

Ionis Stops Development of Inhaled Antisense Therapy for CF

Drug Development

May 10, 2021

FDA Grants Fast-Track Designation to Smart Immune’s T Cell Immunity Enhancement Product

RARECast Podcasts

May 7, 2021

Putting the Patient at the Center of Rare Disease Clinical Trials

Finance

May 7, 2021

Talaris Raises $150 Million in IPO to Advance Cell Therapy Pipeline

Finance

May 7, 2021

Science 37 to Become Publicly Listed via Merger with SPAC

Drug Development

May 7, 2021

ChemoCentryx Continues Slide on Divided FDA Advisory Committee Votes

Drug Development

May 7, 2021

Orphazyme Drug Fails in Pivotal Study

Rare Advocate

May 6, 2021

Rare Leader: Tiffany House, President Acid Maltase Deficiency Association

Finance

May 6, 2021

Dyno Therapeutics Raises $100 Million to Accelerate AI‑powered Gene Therapy Platform

Finance

May 6, 2021

TwinStrand Raises $50 Million to Grow Market for Duplex Sequencing Technology

Deals

May 5, 2021

Amryt Acquires Chiasma, Strengthening Its Rare and Orphan Disease Portfolio

Research

May 5, 2021

Centogene Discovers Six New Rare Diseases

Drug Development

May 5, 2021

ChemoCentryx Shares Crash After FDA Questions Data Supporting ANCA Vasculitis Therapy

Research

May 5, 2021

Study Finds People with Rare Diseases Often Feel Stigmatized

Drug Development

May 4, 2021

Sarepta Reports High-Dose SRP-5051 Increases Dystrophin in Certain DMD Patients

Finance

May 4, 2021

Mogrify Raises $17 Million to Advance Reprogrammed Cell Therapies

Deals

May 4, 2021

Passage Bio Partners with InformedDNA to Offer Genetic Counseling and Testing for FTD

Regulatory

May 4, 2021

Acella Issues Voluntary Nationwide Recall of Certain Lots of Thyroid Tablets Due to Sub Potency

Finance

May 3, 2021

Affinia Raises $110 Million to Advance Engineered AAV Gene Therapy Vector Platform

Finance

May 3, 2021

Aceragen Launches with $35 Million and Experimental Therapy for Farber Disease

Drug Development

May 3, 2021

With Accelerated Approval Off the Table, Avrobio Seeks Registration Trial for Fabry Disease Gene Therapy

Drug Development

May 3, 2021

Alnylam Reports Positive Early Results of Phase 3 PH1 Study

Drug Development

May 3, 2021

FDA Expands Approval of Chiesi’s Ferriprox for Transfusional Iron Overload due to Sickle Cell Disease

RARECast Podcasts

April 30, 2021

Creating a Toolkit to Accelerate the Development of Gene Editing Therapies

Rare Advocate

April 29, 2021

Rare Leader: Nancy Lazarus, Founder, Achalasia Awareness Organization

Finance

April 29, 2021

Capsida Debuts with $140 Million to Advance Next Generation Gene Therapies

Deals

April 29, 2021

Mirum Grants CANbridge Exclusive License to Maralixibat in Greater China for Rare Liver Diseases

Drug Development

April 29, 2021

FDA Grants Fast Track to Akari Bullous Pemphigoid Therapy

Drug Development

April 29, 2021

Astellas Takes $532 Million Charge Over Delay of Gene Therapy for XLMTM

Deals

April 28, 2021

Allen Institute and BioMarin Collaborate to Develop Gene Therapies for Rare Brain Diseases

Drug Development

April 28, 2021

FDA Tell Protalix and Chiesi It won’t Grant Accelerated Approval for Fabry Therapy

Deals

April 27, 2021

LogicBio Enters Gene-Editing Collaborations with CANBridge and Daiichi Sankyo

Deals

April 27, 2021

AllStripes Collaborates with NIH’s NCATS to Launch Effort in Rare Disease Diagnosis

Drug Development

April 27, 2021

FDA Removes Clinical Hold on Voyager, Clears IND for Huntington’s Gene Therapy

Drug Development

April 27, 2021

Biogen Will Provide Early Access to Experimental ALS Drug

Drug Development

April 27, 2021

EMA Grants PRIME Designation to Vertex and CRISPR’s Therapy for Transfusion-Dependent Beta Thalassemia

Drug Development

April 27, 2021

AavantiBio Partners with Catalent to Advance Gene Therapies for Rare Genetic Diseases

Regulatory

April 27, 2021

FDA Issues Guidance on Individualized ASOs for Ultra-Rare Conditions

Drug Development

April 26, 2021

FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program

Drug Development

April 26, 2021

FDA Approves ADC Therapeutics’ Zynlonta to Treat Rare Cancer

RARECast Podcasts

April 23, 2021

PTC Looks to Advanced Therapies

Deals

April 23, 2021

CDISC and NORD to Develop Data Standards for Rare Disease

Rare Advocate

April 22, 2021

Rare Leader: Heidi Edwards, President and Founder, Sister’s Hope Foundation

Deals

April 22, 2021

Vertex and Obsidian Enter into Collaboration to Discover Novel Therapies that Regulate Gene Editing

Finance

April 22, 2021

ITM raises $109 Million to Advance Radiopharmaceutical Precision Oncology Pipeline

Finance

April 21, 2021

Code Biotherapeutics Launches with $10 Million to Develop Therapies for Debilitating Genetic Diseases

Finance

April 21, 2021

EdiGene Raises $62 Million to Advance and Scale Up Clinical Translation of Gene Editing Technologies

Drug Development

April 21, 2021

Beam Publishes Data Demonstrating Ability to Rationally Design Base Editors for Precise Editing

Pricing

April 21, 2021

Bluebird Withdraws Zynteglo from German Market, Cuts Workforce

Drug Development

April 21, 2021

EC Grants Approval to GW Pharmaceuticals’ Epidyolex for TSC-Associated Seizures

Uncategorized

April 21, 2021

FDA Grants RMAT Designation to Allogene’s Cell Therapy for Multiple Myeloma

Research

April 20, 2021

The Making of a Gene Therapy for an Ultra-Rare Disease

Drug Development

April 20, 2021

FDA Puts Clinical Hold on KalVista’s HAE Therapy

Deals

April 20, 2021

Citrine and Sinopharm Enter Strategic Partnership to Broaden Access to Rare Disease Drugs in China

Deals

April 20, 2021

Vertex and CRISPR Amend Sickle Cell Disease and Beta Thalassemia Collaboration

Research

April 20, 2021

IndoUSrare and Rare-X Conduct Feasibility Study for a Patient-Owned Health Data Collection Program for India

Business

April 20, 2021

Castle Creek Biosciences Appoints Matthew Gantz as President and CEO

Finance

April 19, 2021

Rezolute Enters $30 Million Debt Agreement to Advance Rare and Metabolic Disease Pipeline

Drug Development

April 19, 2021

Study Finds Positive Impact of Fintepla on Dravet Patients and Caregivers

Drug Development

April 19, 2021

Biogen Reports New Spinraza Data in SMA

RARECast Podcasts

April 16, 2021

Going to Extreme Lengths

Research

April 16, 2021

Study Identifies Key Target in Treatment-Resistant Hemophilia A

Finance

April 16, 2021

Recursion Raises $436 Million in Upsized IPO to Advance Rare Disease Pipeline

Rare Advocate

April 15, 2021

Lauren Dunlap, Co-Founder and Executive Director, AAIDA

Finance

April 15, 2021

Medable Raises $78 Million to Decentralize Clinical Trials

Finance

April 15, 2021

Alchemab Raises $82 Million to Advance Antibody Therapeutics in Neurodegeneration and Cancer

Deals

April 15, 2021

Ciitizen Partners with STXBP1 Foundation to Accelerate Patient Outcomes

Business

April 15, 2021

DOJ Subpoenas Documents from Alnylam Over Marketing of Onpattro

Drug Development

April 15, 2021

FDA Grants Rare Pediatric Disease Designation to FibroGen Treatment for DMD

Drug Development

April 15, 2021

New Evrysdi Data Shows Improvement in Motor Function Over Time for SMA Patients

Finance

April 14, 2021

Investment in Rare Disease Drug Development Continues to Surge

Research

April 14, 2021

Gene Therapy Shows Promise in Treating Rare Eye Disease in Mice

Deals

April 14, 2021

Huma Enters Partnership with RARE-X to Accelerate Rare Disease Research

Drug Development

April 14, 2021

FDA Grants Rare Pediatric Disease Designation to Therapies from Moleculin and Akuous

Deals

April 13, 2021

Senti Bio and Spark Collaborate to Develop Next-Generation Precision Gene Therapies

Deals

April 13, 2021

BridgeBio Pharma Enters Seven Collaborations with University Partners

Finance

April 13, 2021

Theseus Debuts with $100 Million Series B to for Targeted Treatment-Resistant Cancer Mutations

Finance

April 13, 2021

Arcellx Raises $115 Million to Advance Pipeline of Adaptive and Controllable Cell Therapies

Finance

April 13, 2021

Jaguar Gene Therapy Closes $139 Million Funding to Advance Preclinical Rare Disease Pipeline

Deals

April 13, 2021

ChemGenes to Provide n-Lorem Support for ASO Manufacturing

Deals

April 12, 2021

Taysha Acquires Global Rights to Experimental Gene Therapy for Rare Neurodegenerative Disease

Deals

April 12, 2021

Aytu Licenses Late-Stage Pediatric Onset Rare Disease Asset from Rumpus Therapeutics

Deals

April 12, 2021

Mirum Signs Option to License Vivet’s Experimental Gene Therapy Programs for PFIC

Deals

April 12, 2021

Sanofi Acquires Tidal Therapeutics with Its Innovative mRNA-based Research Platform

Drug Development

April 12, 2021

FDA Grants FibroGen Fast Track Designation for DMD Therapy

RARECast Podcasts

April 9, 2021

Everything’s up to Date in Kansas City, at Least When It Comes to Genomics

Finance

April 9, 2021

Two Rare Disease Biotechs Go Public, Raising Combined $222 Million in IPOs

Finance

April 8, 2021

ValenzaBio Raises $70 million in Venture Round

Finance

April 8, 2021

Three Rare Disease Biotechs Raise Combined $675 Million in Public and Private Offerings

Finance

April 8, 2021

Dicerna Sells Oxlumo Royalty Interest to Royalty Pharma for up to $240 Million

Rare Advocate

April 8, 2021

Rare Leader: Melody Burchett, President, A Cure In Sight

Strategy

April 7, 2021

Ionis Signs Distribution Deal with Sobi and Cuts 70 Percent of Akcea Workforce

Science & Technology

April 7, 2021

U.K.’s University of Sheffield Establishes New Gene Therapy Innovation Center

Finance

April 7, 2021

Metagenomi Extends Series A Financing to Advance Next-Gen Gene Editing Technology

Research

April 7, 2021

NIH Scientists Develop Breath Test for Rare Metabolic Condition

Research

April 7, 2021

Harvard Awards First Round of Rare Cancer Research Grants

Drug Development

April 7, 2021

FDA Grants Breakthrough Therapy to Taiho’s Treatment for Advanced Cholangiocarcinoma

Deals

April 6, 2021

Invitae Acquires Personalized Oncology Testing Company Generosity, Scores $1.2 B Financing

Drug Development

April 6, 2021

Progenity and Ionis Pharmaceuticals Enter into Agreement for Oral Delivery of Antisense Therapies

Drug Development

April 6, 2021

Scholar Rock Reports Positive Topline Results from Therapy for SMA Types 2 and 3

Research

April 5, 2021

Foundation for USP7 Related Diseases Makes Grant to Neurolentech

Drug Development

April 5, 2021

n-Lorem Enters Partnership with Ultragenyx for Personalized Treatments for Patients with Ultra-Rare Conditions

Drug Development

April 5, 2021

FDA Approves Praluent as Add-on Therapy for Patients with HoFH

Drug Development

April 5, 2021

Takeda’s Rare Disease Drug Natpara Won’t Be Available for Another Year

RARECast Podcasts

April 2, 2021

Choosing the Right Viral Vector for a Gene Therapy

Research

April 2, 2021

Penn Researchers Restore Vision in Blind Patient with Rare Genetic Condition with RNA Therapy

Rare Advocate

April 1, 2021

Rare Leader: Marissa Penrod, Founder and CEO, Team Joseph

Strategy

April 1, 2021

Nitto to Invest $226 Million to Expand Oligonucleotide Manufacturing in Massachusetts

Deals

April 1, 2021

Eloxx Acquires Zikani to Focus on Ribosomal RNA-Targeted Gene Therapy

Drug Development

April 1, 2021

FDA Approves New Orphan Indications for Three Marketed Drugs

Research

April 1, 2021

Uplifting Athletes Issues $140,000 in Rare Disease Research Grants

Deals

March 31, 2021

BridgeBio’s QED Therapeutics Enters Blockbuster Partnership with Helsinn for Infigratinib

Finance

March 31, 2021

Scribe Raises $100 Million to Further Develop Its “CRISPR by Design” Platform

Finance

March 31, 2021

Entrada Raises $116 Million to Advance Intracellular Biologics Pipeline into the Clinic

Drug Development

March 31, 2021

Forma Reports Positive Data in SCD Trial

Drug Development

March 30, 2021

Europe Approves Incyte’s Pemazyre for Rare Cancer

Finance

March 30, 2021

Omega Raises $126 Million to Advance Epigenomic Programming Pipeline and Platform

Drug Development

March 30, 2021

Wave Dumps Two Huntington’s Treatments after Failure to Show Benefit in Studies

Finance

March 30, 2021

CZI Begins New Round of Funding for Rare Disease Organizations

Finance

March 30, 2021

Imara Opens Applications for Real Impact Grants

Policy

March 29, 2021

Report Finds Most Rare Disease Drugs Protected by Patents Rather than Exclusivity

Drug Development

March 29, 2021

Ionis Reports Positive Topline Phase 2 Data of Antisense Treatment for HAE

Drug Development

March 29, 2021

Cyclo NPC1 Phase 1/2 Trial Hits Primary Endpoint

Drug Development

March 29, 2021

FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma

Drug Development

March 29, 2021

Orphazyme’s Treatment for Rare Muscle Wasting Disease Fails in Late Stage Trial

RARECast Podcasts

March 26, 2021

A Software Platform to Give Patients the Tools to Build Treatments for Rare Genetic Diseases

Finance

March 26, 2021

Two Rare Disease Drug Developers Raise Combined $416 Million in IPOs

Finance

March 26, 2021

Gyroscope Raises $148 Million to Advance AMD Gene Therapy

Drug Development

March 26, 2021

FDA Expands Use of Myrbetriq to Include Rare Pediatric Indication

Drug Development

March 26, 2021

FDA Approves Kiniksa’s Pericarditis Therapy Arcalyst

Rare Advocate

March 25, 2021

Rare Leader: Lisa Bonebrake, Executive Director, Alport Syndrome Foundation

Diagnosis

March 25, 2021

Sanford Health Enters Partnership with Congenica to Provide Answers for Undiagnosed Rare Disease Patients

Finance

March 24, 2021

Rare Disease Drug Developers’ Deals and IPOs Boost February Numbers

Finance

March 24, 2021

Step Pharma Raises $41.3 Million to Advance First-in-Class Therapy to Clinic in T Cell Malignancies

Innovation

March 24, 2021

Horizon Therapeutics Launches Prize with MIT to Advance Solutions for the Rare Disease Community

Drug Development

March 24, 2021

FDA Grants Fast Track Designation to Reneo’s PMM Therapy

Drug Development

March 24, 2021

ProQR Reports Positive Results of QR-421a in Usher Syndrome

Research

March 24, 2021

Researchers Find New Genetic Links to Rare Eye Disease

Uncategorized

March 23, 2021

PhoreMost Raises $46 Million to Advance Brain Cancer Treatment into Clinic

Drug Development

March 23, 2021

Maze Therapeutics Reveals First Three Programs Targeting Genetic Drivers of Disease

Drug Development

March 23, 2021

Genentech Halting Late-Stage Huntington’s Disease Study

Drug Development

March 23, 2021

Recordati Reports Positive Results from Late-Stage Cushing’s Disease Study

Drug Development

March 22, 2021

Study Shows Proof-of-Concept of Gene Editing in DMD

Diagnosis

March 22, 2021

Whole Genome Sequencing Enables Rare Disease Diagnoses

Drug Development

March 22, 2021

China Grants Citrine Clinical Trial Waiver for Narcolepsy Therapy Wakix

Finance

March 22, 2021

Aura Raises $80 Million to Advance Pipeline Targeting Rare Ocular Cancers

Strategy

March 22, 2021

VeriSIM Launches PulmoSIM to Develop Treatments for Rare Respiratory Diseases

Drug Development

March 22, 2021

BridgeBio’s Calcilytix Reports Proof-Of-Concept for ADH1 Therapy

RARECast Podcasts

March 19, 2021

Side Effects: The Toll a Rare Disease Can Take on a Family in Pursuit of a...

Finance

March 18, 2021

Two Rare Disease Biotechs Rake in $170 Million in Public Equity Offerings

Drug Development

March 18, 2021

Sarepta Reports Positive 2-Year Results from LGMD2E Gene Therapy Trial

Business

March 18, 2021

Chris Austin Will Leave NCATS to Join VC Firm Flagship Pioneering

Finance

March 18, 2021

Gain Therapeutics Raises $40M in IPO to Advance Rare Disease Pipeline

Rare Advocate

March 18, 2021

Rare Leader: Melanie McKay, Founder, Ryker’s Foundation for Pompe Disease

Deals

March 18, 2021

Anima and Takeda to Collaborate on Neurological Disease Therapeutics

Drug Development

March 18, 2021

Translate Bio Reports Results from Trial of mRNA Therapy for Cystic Fibrosis

Deals

March 17, 2021

Amathus and Merck Enter into Neurodegenerative Disease Pact

Deals

March 16, 2021

GBT In-Licenses Two Sickle Cell Small Molecule Programs from Sanofi

Finance

March 16, 2021

StrideBio Raises $81.5M to Advance AAV-Based Gene Therapies into Clinic

Research

March 16, 2021

Scientist Develop Novel Gene Editor to Correct CF and Other Mutations

Drug Development

March 16, 2021

Genentech Reports Positive New Data for Evrysdi in SMA Type 2 or Type 3

Drug Development

March 16, 2021

Nurix Enters Pediatric Cancer Collaboration Sponsored by ALSF

Drug Development

March 16, 2021

Solid Reports New Data from DMD Clinical Trial, Resumes Patient Dosing

Drug Development

March 15, 2021

Bluebird bio Reports Positive Long-Term Data for CALD Gene Therapy

Finance

March 15, 2021

Graphite Raises $150 Million to Advance Gene Editing Therapies for Rare Diseases

Deals

March 15, 2021

Genevant and Takeda Partner to Develop RNA Therapies for Liver Fibrosis

Finance

March 15, 2021

ElevateBio Raises $525M to Advance Cell/ Gene Therapy Business Model

Finance

March 15, 2021

Savara Raises $130 Million to Advance Development of aPAP Therapy

RARECast Podcasts

March 12, 2021

Realizing the Potential of CRISPR Gene Editing

Legislation

March 12, 2021

Congress Introduces Legislation Intended to Speed Development of Rare Disease Therapies

Finance

March 12, 2021

Longboard Raises $80 Million in IPO to Advance Rare Neurological Pipeline

Rare Advocate

March 11, 2021

Rare Leader: Blynda Killian, President, Cyclic Vomiting Syndrome Association

Drug Development

March 11, 2021

Intellia Presents Preclinical Proof of Concept for CRISPR-Based in Vivo Editing

Deals

March 11, 2021

Science 37 and Xperiome Partner to Speed Rare Disease Studies for Patients and Providers

Rare Patient

March 11, 2021

FDA Approves Compassionate Use of Longeveron Therapy in Child with Rare Heart Defect

Drug Development

March 11, 2021

Inability to Enroll Patients Terminates More Than a Quarter of Rare Disease Drug Trials

Regulatory

March 10, 2021

FDA Approves Second Sight Medical Products’ Retinal Prosthesis System

Drug Development

March 10, 2021

Bluebird Says Case of AML Unlikely Related to Gene Therapy Vector

Drug Development

March 10, 2021

FDA Tells Soleno It Will Need to Conduct Additional Study for Prader-Willi Therapy

Drug Development

March 9, 2021

Spinal Muscular Atrophy Foundation and PTC Therapeutics Expand Partnership

Drug Development

March 9, 2021

FDA Grants RMAT Designation to Rocket’s Gene Therapy for Rare Pediatric Disease LAD-I

Drug Development

March 8, 2021

FDA Approves Kite’s Yescarta for Relapsed or Refractory Follicular Lymphoma as Third Line Therapy

Policy

March 8, 2021

NICE Recommends Novartis’ Gene Therapy for SMA

Drug Development

March 8, 2021

AnaptysBio’s Experimental Therapy for Palmoplantar Pustulosis Fails in Phase 2 Trial

Drug Development

March 8, 2021

FDA Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates for Rare CNS Disorders

Drug Development

March 8, 2021

FDA Grants BioMarin RMAT Designation for Experimental Hemophilia A Gene Therapy

RARECast Podcasts

March 5, 2021

Understanding the Economic Toll of Rare Disease in the United States

Drug Development

March 5, 2021

FDA Approves Genentech’s Actemra to Slow Decline in Pulmonary Function in Adults with SSc

Policy

March 5, 2021

Rare Diseases Account for 11 percent of U.S. Drug Spending, Report Finds

In Rare Form

March 4, 2021

When Blockbusters Garner the Benefits of Orphan Drugs

Rare Advocate

March 4, 2021

Rare Leader: Danae’ Bartke, executive director and co-founder, HCU Network America

Policy

March 4, 2021

Advocacy Groups Call on Governors to Prioritize Vaccination of Rare Disease Patients and Caregivers

Strategy

March 4, 2021

Biogen Will Construct $200 Million Gene Therapy Manufacturing Facility in North Carolina

Deals

March 3, 2021

Takeda Secures Global Rights to Rare Epilepsy Treatment from Ovid for $860 Million

Finance

March 3, 2021

Caribou Raises $115 Million to Advance Next-Generation CRISPR Technologies

Research

March 3, 2021

Study Shows Potential for Lipid Nanonparticles to Deliver Gene Editing Therapy to Liver

Drug Development

March 2, 2021

FDA approves Oncopeptides’ Multiple Myeloma Therapy

Finance

March 2, 2021

eGenesis Completes $125 Million Financing

Finance

March 2, 2021

Mesoblast Raises $110 Million

Healthcare

March 2, 2021

Children’s National Hospital Rare Disease Institute Partners with Takeda to Standardize Care for Patients with Rare...

Healthcare

March 2, 2021

GBT Grant Program to Support to the Sickle Cell Disease Community

Finance

March 1, 2021

DTx Pharma Raises $100 Million to Advance its Platform and Pipeline of RNA Therapeutics

Drug Development

March 1, 2021

FDA Grants BridgeBio and Its Affiliate Origin Biosciences Approval for MoCD Therapy

Finance

March 1, 2021

SalioGen Therapeutics Emerges from Stealth, Closes $20 Million Series A

Research

March 1, 2021

Ionis Establishes New Grant Program to Advance Research and Understanding of ATTR

RARECast Podcasts

February 26, 2021

The Promise of Gene-Based Therapies for Neurodegenerative Conditions

Policy

February 25, 2021

When a Dollar Sign Becomes an Exclamation Point

Drug Development

February 25, 2021

Former AveXis Executives Launch Jaguar Gene Therapy to Target Rare Diseases

Rare Advocate

February 25, 2021

Rare Leader: Mark Stone, President and CEO, FSHD Society

Drug Development

February 25, 2021

FDA Grants Rare Pediatric Disease Designation to Retrotope’s Therapy for Two Neurodegenerative Indications

Finance

February 24, 2021

Orna Raises $80 Million to Develop a New Class of Engineered RNA Therapies

Deals

February 24, 2021

Scailyte and Volv Global Enter Strategic Partnership

Deals

February 24, 2021

Children’s Mercy Kansas City Expands Sequencing Capabilities

Deals

February 24, 2021

Cyprium and Sentynl Sign Development and Purchase Agreement for Menkes Disease Therapy

Uncategorized

February 23, 2021

Shepherd Enters Collaboration with NCATS to Improve Treatments for Rare Head and Neck Cancer

Deals

February 23, 2021

Soleno Collaborates with Vanderbilt on KATP Channel Activators for the Treatment of Rare Diseases

Deals

February 23, 2021

Day One Licenses Merck KGaA’s MEK Inhibitor Pimasertib, Expands Pipeline

Deals

February 23, 2021

BC Platforms Partners with Genomenon to Boost Rare Disease Diagnostics and Research

Deals

February 23, 2021

Beam Completes Acquisition of GuideTx

Drug Development

February 23, 2021

Protalix and Chiesi Report Positive Results from Open-Label, Switch Over Trial of Therapy for Fabry Disease

Drug Development

February 22, 2021

FDA Tells BrainStorm Evidence Appears Lacking to Support Seeking Approval for ALS Therapy

RARECast Podcasts

February 19, 2021

Moving Beyond Viral Vectors for Gene Therapies

Rare Advocate

February 18, 2021

Rare Leader: Paula Evans, founder and chairperson, Foundation for Angelman Syndrome Therapeutics (FAST)

Research

February 18, 2021

NCI Awards $16 Million Grant to Advance Research of Two Rare Cancers

Deals

February 18, 2021

Charles River to Acquire Cell and Gene Therapy Manufacturer Cognate BioServices for $875 million

Innovation

February 18, 2021

FDA Approves First-of-Its-Kind Implant to Treat Rare Bone Disease as a Humanitarian Use Device

Diagnosis

February 18, 2021

FDNA Launches Telehealth AI Telegenetics Platform

Finance

February 18, 2021

Evox Therapeutics Raises $95.4 Million To Advance Exosome-Based Pipeline

Deals

February 18, 2021

Otsuka and Eikonizo to Collaborate on Treatments for ALS and Other Rare Diseases

Deals

February 17, 2021

Novartis Teams with Gates Foundation to Develop an Accessible in Vivo SCD Gene Therapy

Data Center

February 17, 2021

Rare Disease Drug Developers Busy Raising Money in January

Drug Development

February 17, 2021

Health Canada Approves Ultragenyx’ Drug for Group of Rare Metabolic Disorders

Healthcare

February 17, 2021

Eurordis Survey Finds People with Rare Diseases Have Concerns with Quality of Healthcare Experience

Research

February 16, 2021

Study Finds Commercial Genetic Testing Technology Falsely Detects Very Rare Variants

Drug Development

February 16, 2021

Bluebird Bio Temporarily Suspends SCD Gene Therapy Trials after Case of AML

Drug Development

February 16, 2021

FDA Approves Pfizer’s Panzyga to Treatment of Adults with CIDP

Deals

February 16, 2021

Shepherd and Oncoheroes Partner to on Medicines for Rare Cancers

Drug Development

February 16, 2021

FDA Grants Rare Pediatric Disease Designation to Forge’s Gene Therapy for Krabbe Disease

Rare Community

February 12, 2021

Mila Makovec, Recipient of Bespoke ASO for Ultra-Rare Condition, Dies at 10

RARECast Podcasts

February 12, 2021

Acquisitions Help Jazz Build Toward Commercial Crescendo

Research

February 12, 2021

Patients’ Cells Offer Insight into New Gene Therapy Approach to Rare Eye Disease

Finance

February 12, 2021

Travere Raises $175 Million in Public Offering to Advance Rare Kidney Disease Pipeline

Finance

February 12, 2021

Decibel Raises $127 Million in IPO to Advance Gene Therapies for Hearing and Balance Disorders

Drug Development

February 12, 2021

Denali Reports Positive Early Data from Phase 1/2 Study in Hunter Syndrome

Drug Development

February 12, 2021

FDA Grants Rare Pediatric Disease and Orphan Drug Designations to Rescindo’s Treatment for Kabuki Syndrome

Drug Development

February 11, 2021

FDA Approves Regeneron’s Evkeeza for Patients with Ultra-Rare Form of High Cholesterol

Rare Advocate

February 11, 2021

Rare Leader: Monica Coenraads, CEO, Rett Syndrome Research Trust

Finance

February 11, 2021

Cyteir Secures $80 Million for Synthetic Lethalities

Strategy

February 11, 2021

Chinook Tackles Rare Chronic Kidney Diseases

Finance

February 11, 2021

KalVista Raises $193.5 Million in Public Offering to Advance HAE Treatment

Finance

February 11, 2021

Ensoma Launches with $70 Million for In Vivo Gene Therapy, Partners with Takeda

Finance

February 10, 2021

Day One Raises $130 Million to Accelerate New Targeted Cancer Treatments for Children

Deals

February 10, 2021

AbbVie and Caribou Biosciences Enter Collaboration for Off-the-Shelf CAR-T Therapies

Deals

February 10, 2021

Ipsen Enters Agreement with Mendelian to Use Company’s Software to Diagnose Rare Diseases

Drug Development

February 10, 2021

Galapagos and Gilead Discontinue Late-Stage Study in IPF, Stop Development of Drug

Finance

February 10, 2021

HemoShear Raises $40 Million to Advance Rare Disease Portfolio

Finance

February 10, 2021

Mereo BioPharma Raises $100 Million in Public Offering

Drug Development

February 10, 2021

FDA Expands Use of Botox to include Rare Pediatric Neurologic Condition

Research

February 10, 2021

Study Suggests Way to Arrest Two Rare Disease Before Birth

In Rare Form

February 9, 2021

Not the Way it Normally Happens

Drug Development

February 9, 2021

KalVista Reports Positive Results in Trial of Oral Treatment for HAE Attacks

Drug Development

February 8, 2021

Avrobio Reports Positive Results of Its Gene Therapy for Fabry Disease

Business

February 8, 2021

Editas’ Collins Steps Down, Chairman Mullen Takes Reins

Finance

February 8, 2021

Ocugen Raises $23 Million to Advance Ocular Gene Therapies

Drug Development

February 8, 2021

FDA Approves Two Rare Cancer Therapies

RARECast Podcasts

February 5, 2021

Powerful Gene Editing Approach Offers the Promise of Correcting a Range of Rare Diseases

Finance

February 5, 2021

Two Rare Disease Biotechs Hit the Market in Upsized IPOs

Finance

February 5, 2021

Rhythm and Orchard Each Raise $150 Million to Advance Their Rare Disease Programs

Rare Advocate

February 4, 2021

Rare Leader: Karen Chen, CEO, Spinal Muscular Atrophy Foundation

Finance

February 4, 2021

Kaleido Raises $60 Million in Public Offering to Advance Pipeline of Microbiome Targeted Therapies

Finance

February 4, 2021

Sana Raises $588 Million in IPO to Advance Engineered Cell Therapies

Finance

February 4, 2021

Coya Completes Merger and Raises $10 Million to Advance Pipeline of Tregs for Neurodegenerative Diseases

Drug Development

February 4, 2021

Prothena Revives Birtamimab Program in AL Amyloidosis

Deals

February 3, 2021

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals for $7.2 Billion

In Rare Form

February 3, 2021

The Making of A Rare Parent

Deals

February 3, 2021

Neurocrine Terminates Parkinson’s Gene Therapy Collaboration with Voyager Therapeutics

Drug Development

February 2, 2021

Travere Achieves Interim Proteinuria Endpoint in Ongoing Study of Sparsentan in FSGS

Drug Development

February 2, 2021

Immunovant Shares Tumble as It Pauses Clinical Dosing of TED Therapy

Drug Development

February 2, 2021

FDA Removes Clinical Hold on Mustang Gene Therapies for SCID

Drug Development

February 2, 2021

FDA Grants Rare Pediatric Disease Designation to Chinook’s Treatment of Primary Hyperoxaluria

Deals

February 1, 2021

Horizon to Acquire Viela Bio to Expand Pipeline and Grow Rare Disease Portfolio

Research

February 1, 2021

CHOP Researchers Develop Improved Vector for Blood Disorder Gene Therapies

RARECast Podcasts

January 29, 2021

A Child’s-Eye-View of Clinical Trials

Finance

January 29, 2021

AGTC Raises $74.5 Million to Advance Pipeline of Gene Therapies for Rare Diseases

Deals

January 29, 2021

Catabasis Pharmaceuticals Acquires Quellis Biosciences and Raises $110 Million in Private Offering

Rare Advocate

January 28, 2021

Gina Glass, Executive Director, Dreamsickle Kids Foundation

Policy

January 28, 2021

Health Canada Seeks Input from Canadians on a National Strategy for High-Cost Drugs for Rare Diseases

Drug Development

January 28, 2021

FDA Grants M6P Therapeutics Six Rare Pediatric Disease designations for LSDs

Policy

January 28, 2021

NORD Issues State Report Cards on Policy Issues Critical to Rare Disease Patients

Research

January 27, 2021

Study in Flies Reveals Interaction Between Genes Drives Severity of Ultra Rare Disease

Drug Development

January 27, 2021

Agios’ Mitapivat Meets Primary Endpoint in Late-Stage Study in Pyruvate Kinase Deficiency

Finance

January 27, 2021

Design Secures $125 Million to Advance Treatments for Repeat Expansion Disorders

Drug Development

January 27, 2021

FDA Approves Recordati’s Carbaglu to Treat Acute Hyperammonemia

Finance

January 27, 2021

Catalyst Biosciences Raises $50 Million to Advance Rare Disease Pipeline

Drug Development

January 26, 2021

Rhythm Reports Positive Data with Setmelanotide in Additional Rare Obesities

Finance

January 26, 2021

BridgeBio Prices Upsized Offering of $650 Million Convertible Senior Notes

Deals

January 26, 2021

Relief and Acer Sign Option Agreement for Exclusivity on Treatment for UCDs

Rare Patient

January 25, 2021

Patients with Chronic Rare Conditions Feel Unsupported

Drug Development

January 25, 2021

Eiger Launches Zokinvy for Treatment of Progeria

RARECast Podcasts

January 22, 2021

Using Nanoliposomes to Make Cancer Therapies Safer and More Effective

Finance

January 22, 2021

Spate of Public Offerings Continues as Two More Companies Raise Capital in Public Markets

Drug Development

January 21, 2021

A Year of Many Firsts

Rare Advocate

January 21, 2021

Rare Leader: Keith Harper, Board President, Narcolepsy Network

Finance

January 21, 2021

Editas Medicine and Dyne Therapeutics Raise Combined $399 Million in Public Offerings

Drug Development

January 20, 2021

EC Approves Extension of SOBI’s Doptelet for ITP

Drug Development

January 20, 2021

UCSD and Ionis Use ASO to Target Multiple Myeloma

Finance

January 20, 2021

Three Rare Disease Companies Raise Combined $380 Million in Public Offerings

Drug Development

January 19, 2021

FDA Grants Taysha Rare Pediatric Disease Designation for SLC13A5 Deficiency Candidate

Drug Development

January 18, 2021

FDA Approves Janssen’s Darzalex Faspro to Treat Newly Diagnosed AL Amyloidosis

RARECast Podcasts

January 15, 2021

Accelerating Treatments for Rare Disease through Data Sharing

Rare Advocate

January 14, 2021

Rare Leader: Heidi Wallis, President, Association for Creatine Deficiencies

Deals

January 14, 2021

Sarepta and Genevant Enter Research Collaboration for LNP-Based Gene Editing Therapeutics

Finance

January 14, 2021

Aldeyra Therapeutics Raises $65 Million to Advance Therapies Targeting Immune-Mediated Diseases

Drug Development

January 14, 2021

FDA Grants RMAT Designation to Orchard Therapeutics Treatment for Metachromatic Leukodystrophy

Innovation

January 13, 2021

Study Suggests Genetic Editing Could Correct Rare Disease that Causes Rapid Aging

Strategy

January 13, 2021

Taysha and UT Southwestern Launch Innovation Fund to Advance CNS Gene Therapies into Clinic

Drug Development

January 13, 2021

Inzen Therapeutics Unveiled to Explore Novel Medicines Based on Input from Dying Cells

Finance

January 12, 2021

Tessera Raises More Than $230 Million to Advance ‘Gene Writing’ Platform

Uncategorized

January 11, 2021

The United Kingdom Releases a Rare Disease Framework

Finance

January 11, 2021

Atalanta Therapeutics Launches $110 Million to Pioneer RNAi Therapeutics for Neurodegenerative Diseases

Strategy

January 11, 2021

Bluebird Bio Retains Gene Therapy and Spins Out Oncology into Separate Company

Drug Development

January 8, 2021

Sarepta DMD Gene Therapy Meets Primary Endpoint but Fails to Show Functional Benefit, Shares Fall

RARECast Podcasts

January 8, 2021

Treating the Root Cause of Sickle Cell Disease

In Rare Form

January 7, 2021

FDA Issues Guidance on Individualized Medicines

Finance

January 7, 2021

A Stellar Year for Rare Disease Financings

Rare Advocate

January 7, 2021

Rare Leader: Nasha Fitter, CEO, FOXG1 Research Foundation

Finance

January 7, 2021

Lexeo Therapeutics Launches with $85 Million to Develop Gene Therapies for Monogenic Diseases

Finance

January 7, 2021

Abcuro Raises $42 Million to Develop Immune Modulating Therapies

Deals

January 7, 2021

Argenx and Zai Lab Enter Strategic Collaboration to Expand Reach of Autoimmune Therapy

Finance

January 7, 2021

Endeavor BioMedicines Launches with $62 Million to Attack Idiopathic Pulmonary Fibrosis

Drug Development

January 7, 2021

Alnylam Reports Positive Topline Results from Late-Stage hATTR Study

Finance

January 7, 2021

Gene Therapy Developer Generation Bio Raises $196 Million in Public Offering

Drug Development

January 7, 2021

FDA Grants Rare Pediatric Disease Designations to Inversago and to Praxis Precision Medicines

Deals

January 6, 2021

Rhythm Pharmaceuticals Sells Priority Review Voucher to Alexion for $100M

Deals

January 6, 2021

Mount Sinai and Rumi Scientific Partner to Advance Drug Discovery for Rare Genetic Disorders Tied to...

Deals

January 5, 2021

Biogen and ViGeneron Enter into Global Development Collaboration for Ophthalmic Gene Therapy

Finance

January 5, 2021

Aro Biotherapeutics Raises $88 Million to Advance Development of Genetic Medicines

Finance

January 5, 2021

A Go-Go Market for Rare Disease IPOs

Finance

January 5, 2021

A Banner Year for Venture Funding

Finance

January 5, 2021

Rare Disease Secondary and Debt Offerings Rise in 2020

Finance

January 5, 2021

Rare Partnering Slows in 2020, but Deal Values Grow

Finance

January 5, 2021

AstraZeneca Acquisition of Alexion Tops M&A in 2020

Deals

January 4, 2021

Taysha Gene Therapies Collaborates with AllStripes on Leigh Syndrome

RARECast Podcasts

December 31, 2020

Targeting A Common Pathway in Genetic Forms of Obesity

Deals

December 30, 2020

Incyte and Cellenkos Enter into Global Development Collaboration of Combo Treatment for Myelofibrosis

Drug Development

December 30, 2020

Protalix and Chiesi Report Final Results of Phase 3 Study of Therapy for Fabry Disease

Research

December 29, 2020

HKUMed Researchers Discover Novel Gene Implicated in Rare Heterotaxy Syndrome

Drug Development

December 28, 2020

Aprea’s Experimental Therapy Misses Primary Endpoint in Late Stage MDS Trial

Drug Development

December 28, 2020

United Therapeutics Acquires Rare Disease Priority Review Voucher

Drug Development

December 28, 2020

FDA Lifts Hold on Audentes’ Gene Therapy Trial for the Treatment of X-Linked Myotubular Myopathy

RARECast Podcasts

December 24, 2020

After Pruning Orchard, Gaspar Focuses on High Value Opportunities

Rare Advocate

December 24, 2020

Rare Leader: Allison Kaczenski, Founder and President, SATB2 Gene Foundation

Finance

December 23, 2020

RegenxBio Sells Portion of Zolgensma Royalties for $200 Million

Drug Development

December 23, 2020

FDA Grants Rare Pediatric Disease Designation to Novadip’s Treatment for Rare Bone Disease

Deals

December 23, 2020

BridgeBio Enters Collaboration with UCSF to Accelerate the Development of Therapies for Genetic Diseases

Deals

December 22, 2020

Vertex Partners with Skyhawk to Modulate RNA Splicing for Serious Diseases

Drug Development

December 22, 2020

Rhythm Obesity Drug Hits Endpoint in Bardet-Biedl Patients, but Misses in Alström Syndrome Patients

Deals

December 21, 2020

Agios Sells Oncology Business for $2 Billion to Focus on Genetic Diseases

Drug Development

December 21, 2020

FDA Places Clinical Hold on UniQure Hemophilia B Gene Therapy Program

RARECast Podcasts

December 18, 2020

Writing a New Chapter of Genetic Medicine

Deals

December 18, 2020

Mereo BioPharma and Ultragenyx Partner to Develop Setrusumab for Rare Bone Disease

Deals

December 18, 2020

GSK and Adrestia and Enter into Precision Medicine Discovery Collaboration

Drug Development

December 18, 2020

FDA Grants Rare Pediatric Disease Designation to Polaryx Therapeutics’ Treatment for Niemann Pick Disease

Rare Advocate

December 17, 2020

Rare Leader: Mike Graglia, Managing Director, Syngap Research Fund

In Rare Form

December 17, 2020

Reengineering Gene Therapy Development

Deals

December 17, 2020

Novartis to Acquire Cadent Therapeutics for Up to $770 Million

Finance

December 16, 2020

Neurogene Raises $115 Million to Advance Gene Therapies for Rare Neurological Diseases

Finance

December 16, 2020

Atsena Therapeutics Raises $55 Million to Advance LCA1 Gene Therapy

Drug Development

December 16, 2020

Sio Gene Therapies Reports Positive Early Data from Gene Therapy for GM1 Gangliosidosis

Deals

December 15, 2020

Lilly to Acquire Gene Therapy Developer Prevail Therapeutics for $1 Billion

Finance

December 15, 2020

Mirum Pharmaceuticals Raises $75 Million in Public Offering

Deals

December 15, 2020

Centene Signs Agreement to Acquire PantheRx Rare Pharmacy

Deals

December 15, 2020

AnGes Acquires Gene Editing Company EmendoBio

Deals

December 14, 2020

AstraZeneca Moves into Rare Disease with $39 Billion Acquisition of Alexion

Finance

December 14, 2020

Locanabio Raises $100 Million to Advance RNA-Targeted Gene Therapies

Finance

December 14, 2020

InnoSkel Launches with $24 Million to Tackle Rare Skeletal Diseases

Deals

December 14, 2020

EspeRare Foundation and Pierre Fabre Collaborate to Market XLHED Therapy

RARECast Podcasts

December 11, 2020

How an Ultra-Rare Disease Patient Organization Drove Research to a Treatment

Finance

December 11, 2020

Three Rare Disease Drug Developers Raise a Combined $430 Million

Finance

December 11, 2020

Gene Therapy Developer 4D Molecular Therapeutics Raises $193.2 Million in Upsized IPO

Drug Development

December 11, 2020

Savara Ends Development of CF Therapy After Phase 3 Study Fails, Announces Reorganization

Finance

December 10, 2020

Faze Launches with $81 Million to Leverage Biology of Biomolecular Condensates to Treat Disease

Rare Advocate

December 10, 2020

Rare Leader: Mika Covington, President, Next Generation of Cystinosis

Drug Development

December 10, 2020

Apellis and Sobi Report Therapy Demonstrated Sustained Improvement in Late-Stage PNH Study

Finance

December 10, 2020

Wood Capital Advisors Donates $500,000 to n-Lorem Foundation

Drug Development

December 10, 2020

FDA Grants Rare Pediatric Disease Designation to X4 Pharma’s Treatment for WHIM Syndrome

Drug Development

December 9, 2020

Pluristem to Halt Development of Critical Limb Ischemia Therapy

Finance

December 9, 2020

Mirum Pharmaceuticals Enters into $210 Million Funding Arrangement with Oberland Capital

Finance

December 9, 2020

Four Companies Raise $380.5 Million in New Capital to Advance Their Rare Disease Programs

Finance

December 9, 2020

PepGen Raises $45 Million to Advance Oligonucleotide Platform Targeting Rare Neuromuscular and Cardiac Diseases

Deals

December 9, 2020

Illumina and Harvard Pilgrim Expand Access to Whole-Genome Sequencing through Risk-Sharing Agreement

Finance

December 9, 2020

Reneo Raises $95 Million to Advance Rare Mitochondrial Disease Pipeline

Finance

December 8, 2020

Vigil Launches with $50 Million to Develop Therapeutics for Neurodegenerative Diseases

Finance

December 8, 2020

Arcturus Therapeutics Raises $150 Million in Public Offering

Finance

December 8, 2020

Remix Launches with $81 Million to Fund Pipeline of RNA Therapies

Deals

December 8, 2020

Amolyt Pharma Enters Into Acromegaly Research Collaboration with PeptiDream

Drug Development

December 8, 2020

Sarepta Reports Positive Results from Mid-Stage Study of DMD Therapy

Finance

December 7, 2020

BioCryst Secures $325 Million of Funding in Royalty Deal

Deals

December 7, 2020

Maze Forms Two Joint Ventures to Translate Genetic Insights into New Medicines

Deals

December 7, 2020

Atara Biotherapeutics Enters Strategic Collaboration with Bayer for Mesothelin-Targeted CAR T-Cell Therapies

Deals

December 7, 2020

Syros Acquires Clinical Candidate for the Treatment of Rare Blood Cancer from Orsenix

Research

December 7, 2020

Discovery Points Toward Approach to Treating Set of Rare Diseases

In Rare Form

December 4, 2020

A Christmas Like No Other

RARECast Podcasts

December 4, 2020

With a New Identity, Travere Thearpeutics Seeks to Find Its True Path

Finance

December 4, 2020

Sigilon Raises $126 Million in IPO to Advance Its “Living Therapeutics” Platform

Finance

December 4, 2020

CureDuchenne Ventures Collaboration Backs Mesentech’s Effort to Address Bone Wastage in DMD

Deals

December 4, 2020

Magenta and Bluebird Bio Collaborate on SCD Study

Deals

December 4, 2020

Tevard and Zogenix Collaborate to Advance Gene Therapies for Genetic Epilepsies

Deals

December 4, 2020

FDA Approves First Oral, Once-daily Therapy to Prevent HAE Attacks

Rare Advocate

December 3, 2020

Rare Leader: Christine Von Raesfeld, Founder and CEO, People with Empathy

Policy

December 3, 2020

Ohio Advances Legislation to Create Rare Disease Advisory Council

Drug Development

December 3, 2020

FDA Approves Vanda’s Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome

Diagnosis

December 3, 2020

U.K.’s NHS Launches Rare Disease Diagnosis Program

Finance

December 2, 2020

Intellia Therapeutics Raises $175 Million in Public Offering

Drug Development

December 2, 2020

Ovid’s Experimental Angelman Therapy Fails in Phase 3 Study

Drug Development

December 2, 2020

FDA Grants Fast Track Designation to Two Therapies for Hematological Disorders

Drug Development

December 2, 2020

GBT Initiates Early Access Program for SCD Patients in Europe

Finance

December 1, 2020

Noema Pharma Launches with $59 Million to Tackle Rare Neurological Disorders

Finance

December 1, 2020

Canbridge Pharmaceuticals Completes $43 Million Financing to Expand Rare Disease Pipeline

Deals

December 1, 2020

Telix Agrees to Acquire TheraPharm

Drug Development

December 1, 2020

Agios Reports Positive Late-Stage Results of Therapy for PK Deficiency

Drug Development

December 1, 2020

FDA Grants Rare Pediatric Disease Designations to Moleculin and Aeglea

Finance

November 30, 2020

Backed with $800 Million Resilience Aims to Change the Future of Medicine through Manufacturing Innovation

Finance

November 30, 2020

Spotlight Raises $30 Million to Advance Pipeline of Non-Viral CRISPR Gene Editing Therapeutics

Diagnosis

November 30, 2020

New DNA Scanning Method Could Lead to Faster Diagnoses

Policy

November 30, 2020

Eurodis, Rare Impact Offer List of Policies to Improve Access to Advanced Therapies

RARECast Podcasts

November 27, 2020

Making Gene Therapies Accessible to Patient with Ultra-Rare Conditions

Drug Development

November 27, 2020

FDA Approves Rhythm’s Drug for Rare Genetic Diseases of Obesity

Rare Advocate

November 25, 2020

ALS Ice Bucket Challenge Co-Founder Pat Quinn Dies at 37

Drug Development

November 25, 2020

FDA Grants Rare Pediatric Disease Designation to Polaryx’s Treatment for GM2 Gangliosidosis

Drug Development

November 24, 2020

FDA Approves Alnylam’s Oxlumo for the Treatment of Primary Hyperoxaluria Type 1

Drug Development

November 23, 2020

FDA Approves First Treatment for Rare Aging Syndrome

Science & Technology

November 23, 2020

CZI Grant to FOXG1 Research Foundation Seeks to Accelerate Drug Development with Machine Learning

RARECast Podcasts